TVGN Stock Analysis: Buy, Sell, or Hold?
TVGN - Tevogen Bio Holdings Inc. Common Stock
$6.81
0.06 (0.89%)
â˛
5d:
+3.5%
30d:
+51.67%
90d:
-29.14%
WAIT
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Aug 18, 2026
0d
Get Alerted When TVGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: TVGN is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: TVGN is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: TVGN is currently trading at $6.81, which is considered slightly high relative to its 30-day fair value range of $4.90 to $7.00.
Technical Outlook: Technically, TVGN is showing sideways momentum. The price is approaching resistance at $6.90. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TVGN scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. However, the stock is trading significantly above the average Wall Street target of $2.00. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TVGN is showing sideways momentum. The price is approaching resistance at $6.90. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TVGN scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. However, the stock is trading significantly above the average Wall Street target of $2.00. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$4.90 -
$7.00
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
31.6%
All Signals
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BEARISH: Trading 70.4% above Wall St target ($2.00)
- WARNING: Composite score 45/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.90 -
$7.00
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$5.90
Resistance Level
$6.90
Current Trend
Sideways
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.68
Wall Street Target
$2.00
(-70.4%)
Share & Embed Analysis
Last updated: August 24, 2026 4:59 PM ET
Data refreshes hourly during market hours. Next update: 5:59 PM
Data refreshes hourly during market hours. Next update: 5:59 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TVGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Neal Flomenberg
SELL
501 shares
2026-03-13
Neal Flomenberg
SELL
452 shares
2026-03-11
Neal Flomenberg
SELL
19 shares
2026-03-10
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 46 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 45 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 68 BUY |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
13 analysts |
$19 | 51 HOLD |
|
RNA
Atrium Therapeutics, IncâĻ |
STRONG BUY
15 analysts |
$25 | 32 SELL |
